Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

August 31, 2014

Conditions

Multiple Myeloma

Interventions

DRUG

lenalidomide (Revlimid®)

25 mg p.o. daily on days 1-21 of each 28 day cycle

DRUG

Cyclophosphamide

50 mg p.o. BID daily on days 1-21 of each 28 day cycle

DRUG

Prednisone

50 mg p.o. Q.O.D.

Trial Locations (1)

Indiana University Cancer Center, Indianapolis